Using light therapy to relieve mouth pain from chemotherapy in children
Double-blind, Randomized, Multi-center, Non-inferiority Clinical Trial Comparing Two Photobiomodulation Protocols in the Analgesia of Chemotherapy-induced Oral Mucositis in Children
This study tests whether light therapy can help relieve mouth pain from chemotherapy in children aged 3 to 18 by comparing different treatment schedules.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 406 (estimated) |
| Ages | 3 Years to 17 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 16 sites (Toulouse, Occitanie and 15 other locations) |
| Trial ID | NCT04596410 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of photobiomodulation (PBM) using low-level laser therapy (LLLT) to alleviate chemotherapy-induced oral mucositis in children aged 3 to 18 years. The study compares two different application protocols: LLLT applied every other day versus daily application. It aims to establish a standardized protocol for PBM in pediatric patients, addressing the variability in treatment parameters currently reported in the literature. The trial is multicenter, randomized, and double-blind, ensuring robust data collection and analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 3 to 18 years who are hospitalized for cancer treatment and have oropharyngeal mucositis of grade 2 or higher.
Not a fit: Patients with solid cancer lesions in the area of laser application or those who have received prior low-level laser therapy for oral mucositis within two weeks may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve the quality of life for children undergoing chemotherapy by reducing pain and discomfort associated with oral mucositis.
How similar studies have performed: Previous studies have shown promising results for photobiomodulation in pediatric patients, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female children aged ≥ 3 years and \< 18 years. 2. Hospitalization in an oncology or hematology department in the participating centres. 3. Patients with oropharyngeal mucositis of grade 2 or higher (WHO grading system) related to cancer chemotherapy, including conditioning for Hematopoietic Stem Cell Transplantation (HSCT). 4. Written informed consent of both patient's holders of parental authority, and patient's assent when applicable. 5. Patients affiliated to a French Social Security insurance or equivalent social protection. 6. Absence of any physical or psychological disability that may interfere with the LLLT application. Exclusion Criteria: 1. Patients with a solid cancer lesion in the area of low-level laser application. 2. History of cervicofacial radiotherapy. 3. Application of low-level laser therapy for oral mucositis within 2 weeks prior to randomization. 4. Hyperthyroidism defined by TSH \< 0.4 IU/mL at inclusion. 5. Patients susceptible to epilepsy seizure. 6. Patients with pacemaker. 7. Patients refusing to wear retinal goggles during low-level laser 1. Patients with a solid cancer lesion in the area of low-level laser application. 8. Patients protected by law (guardianship and safeguarding of justice). 9. Pregnant female patients as determined by positive serum pregnancy test at screening. 10. Lactating female patients who are actively breast feeding. 11. Participation in another clinical trial involving oral care.
Where this trial is running
Toulouse, Occitanie and 15 other locations
- University hospital of Toulouse — Toulouse, Occitanie, France (Recruiting)
- University hospital of Angers — Angers, France (Recruiting)
- University hospital of Besançon — Besançon, France (Recruiting)
- University hospital of Grenoble — Grenoble, France (Recruiting)
- University hospital of Lille — Lille, France (Recruiting)
- University hospital of Limoges — Limoges, France (Recruiting)
- Hôpital La Timone — Marseille, France (Recruiting)
- University hospital of Nancy — Nancy, France (Recruiting)
- University Hospital of Nice — Nice, France (Recruiting)
- Armand Trousseau Hospital — Paris, France (Recruiting)
- University hospital of Poitiers — Poitiers, France (Recruiting)
- University hospital of Reims — Reims, France (Recruiting)
- University hospital of Rouen — Rouen, France (Recruiting)
- University hospital of Saint-Etienne — Saint-Étienne, France (Recruiting)
- University hospital of Strasbourg — Strasbourg, France (Recruiting)
- University Hospital of Tours — Tours, France (Recruiting)
Study contacts
- Principal investigator: Marlène PASQUET — University Hospital, Toulouse
- Study coordinator: Marlène PASQUET, MD
- Email: pasquet.m@chu-toulouse.fr
- Phone: 05 34 55 86 43
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.